Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Annexin A5

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Annexin A5. Displaying page 1 of 1.
    EudraCT Number: 2021-002200-12 Sponsor Protocol Number: ANN-002 Start Date*: 2021-12-23
    Sponsor Name:MUMC AZm
    Full Title: A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential of intravenously administered ANXV (a recombinant human Annexin A5) in patients with confirm...
    Medical condition: moderate to severe COVID-19 pneumonia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005893-29 Sponsor Protocol Number: atp01 Start Date*: 2008-08-14
    Sponsor Name:RUNMC
    Full Title: Does ATP cause Annexin A5 targeting in the human forearm?
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006706-29 Sponsor Protocol Number: 01 Start Date*: 2007-02-12
    Sponsor Name:UMCN department Pharm-Tox
    Full Title: Does atorvastatin reduce ischemia-reperfusion injury in humans in-vivo?
    Medical condition: ischemia reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028596 Myocardial infarction LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005789-11 Sponsor Protocol Number: atorv02 Start Date*: 2008-03-11
    Sponsor Name:RUNMC
    Full Title: Does atorvastatin have an acute and prolonged inhibitory effect on ischemia-reperfusion injury in humans in-vivo?
    Medical condition: ischemia-reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023033 Ischemia myocardial LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000151-33 Sponsor Protocol Number: rosu01 Start Date*: 2007-04-02
    Sponsor Name:UMCN
    Full Title: Does caffeine reduce rosuvastatin-induced protection against ischemia-reperfusion injury?
    Medical condition: Rosuvastatin is a proven cholesterol lowering medicine. Apart from it’s cholesterol lowering action, rosuvastatin may also increase tolerance against ischemia-reperfusion injury. We hypothesize tha...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000891 Acute myocardial infarction LLT
    9.1 10023033 Ischemia myocardial LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001089-33 Sponsor Protocol Number: 2007-001089-33 Start Date*: 2008-09-23
    Sponsor Name:University Medical Center Groningen, dept. of Cardiology [...]
    1. University Medical Center Groningen, dept. of Cardiology
    2. University Medical Center Nijmegen, dept. of Pharmacology-Toxicology
    Full Title: Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects again...
    Medical condition: Myocardial ischemia-reperfusion injury.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059512 Apoptosis LLT
    9.1 10028601 Myocardial ischemia LLT
    9.1 10051624 Myocardial reperfusion injury LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Nov 06 03:40:57 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA